Fabrice Barlesi

Overview

Best Publications

• Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

  H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  9411
  Citations

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  4515
  Citations

• Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

  Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  3296
  Citations

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

  S Novello;F Barlesi;R Califano;R Califano;T Cufer

  2325
  Citations

• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

  Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  2247
  Citations

• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  1340
  Citations

• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

  David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  1300
  Citations

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

  Ferdinandos Skoulidis;Bob T. Li;Grace K. Dy;Timothy J. Price

  1166
  Citations

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

  J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  1081
  Citations

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  946
  Citations

• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

  Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  932
  Citations

• Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

  Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  913
  Citations

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

  F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  909
  Citations

• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

  Aymeric Silvin;Nicolas Chapuis;Garett Dunsmore;Anne-Gaëlle Goubet

  861
  Citations

• An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

  David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  827
  Citations

• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

  M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  815
  Citations

• Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

  Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  807
  Citations

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  697
  Citations

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  646
  Citations

• Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

  Pascale Tomasini;Laurent Greillier;Arnaud Boyer;Arnaud Jeanson

  18
  Citations